Plant Name: Eleutherococcus gracilistylus
Taxonomic Information:
Plant ID: NPO8500
Plant Latin Name: Eleutherococcus gracilistylus
Taxonomy Genus: Eleutherococcus
Taxonomy Family: Araliaceae
Plant External Links:
NCBI TaxonomyDB:
265764
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| FFAR1; FFAR4; | |
| ALPI; TDP1; P4HB; AKR1B1; ALOX15; ALDH1A1; POLB; | |
| GAA; | |
| CA2; CA12; CA1; CA9; CA14; CA7; CA4; CA6; | |
| PPARA; PPARG; | |
| NR1I2; | |
| KDM4E; | |
| PTGS1; XDH; | |
| CASP1; CASP7; | |
| HIF1A; | |
| MAPT; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
| Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | ALPI | Intestinal alkaline phosphatase | P09923 | CHEMBL5573 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | P4HB | Protein disulfide-isomerase | P07237 | CHEMBL5422 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
| Nuclear hormone receptor subfamily 1 group I | NR1I2 | Pregnane X receptor | O75469 | CHEMBL3401 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.733E-13 | 6.290E-10 | CA1, CA12, CA2, CA4, CA6, CA7, CA9 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 3.460E-09 | 7.534E-06 | CYP2C19, CYP2C9, CYP3A4, NR1I2 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 5.681E-08 | 9.515E-05 | ALPI, CA1, CA12, CA2, CA4, CA6, CA7, CA9, NR1I2, PPARA, PPARG |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 9.054E-08 | 1.408E-04 | CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0065007; biological regulation | GO:0006919; activation of cysteine-type endopeptidase activity involved in apoptotic process | 2.634E-07 | 3.019E-04 | CASP1, CASP7, MAPT, PPARG, XDH |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 1.364E-06 | 1.291E-03 | CYP2C19, CYP2C9, CYP3A4, NR1I2, PTGS1 |
| MF | GO:0003824; catalytic activity | GO:0016705; oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen | 6.174E-06 | 4.201E-03 | CYP2C19, CYP2C9, CYP3A4, P4HB, PTGS1 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 7.207E-06 | 4.616E-03 | ALOX15, CYP2C19, CYP2C9, CYP3A4, XDH |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 8.482E-06 | 5.277E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0051213; dioxygenase activity | 1.626E-05 | 8.581E-03 | ALOX15, KDM4E, P4HB, PTGS1 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.695E-05 | 8.581E-03 | CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.847E-19 | 4.021E-15 | CA1, CA12, CA14, CA2, CA4, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 4.919E-15 | 3.570E-11 | CA1, CA12, CA14, CA2, CA4, CA6, CA7, CA9 |
| CC | GO:0043226; organelle | GO:0097504; Gemini of coiled bodies | 1.848E-04 | 4.680E-02 | SMN1, SMN2 |
| CC | GO:0044464; cell part | GO:0032838; plasma membrane bounded cell projection cytoplasm | 2.020E-04 | 4.998E-02 | AKR1B1, HIF1A, MAPT |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 5.270E-19 | 3.478E-17 | CA12, CA1, CA2, CA4, CA7, CA6, CA9, CA14 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.417E-07 | 4.675E-06 | CYP2C9, ALOX15, CYP3A4, CYP2C19 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 3.202E-06 | 7.045E-05 | CYP2C9, ALOX15, CYP2C19, PTGS1 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 1.998E-05 | 3.297E-04 | CYP2C9, GAA, ALOX15, ALDH1A1, AKR1B1, ALPI, CYP2C19, CYP3A4, XDH, PTGS1 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 3.364E-05 | 4.441E-04 | CYP2C9, ALOX15, CYP2C19, PTGS1 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 1.667E-04 | 1.834E-03 | CYP2C9, ALDH1A1, CYP3A4 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 1.991E-04 | 1.877E-03 | CYP2C9, CYP3A4, CYP2C19 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 3.316E-04 | 2.736E-03 | CYP2C9, CYP3A4, CYP2C19 |
| 09100 Metabolism | 09101 Carbohydrate metabolism | hsa00052 | Galactose metabolism | 1.116E-03 | 7.364E-03 | GAA, AKR1B1 |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 6.536E-04 | 4.793E-03 | CA2, CA4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; CA2; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| NA: NA | Edema | NA | CA2; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
